Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBT Margin (2016 - 2025)

Coherus Oncology (CHRS) has disclosed EBT Margin for 12 consecutive years, with 363.56% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 23249.0% to 363.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 434.23% through Dec 2025, up 38649.0% year-over-year, with the annual reading at 434.23% for FY2025, 38200.0% up from the prior year.
  • EBT Margin hit 363.56% in Q4 2025 for Coherus Oncology, up from 384.73% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 34.12% in Q2 2021 to a low of 2947.83% in Q1 2024.
  • Historically, EBT Margin has averaged 401.75% across 5 years, with a median of 199.52% in 2021.
  • Biggest five-year swings in EBT Margin: crashed -271436bps in 2024 and later soared 232409bps in 2025.
  • Year by year, EBT Margin stood at 62.26% in 2021, then crashed by -108bps to 129.79% in 2022, then surged by 33bps to 87.03% in 2023, then tumbled by -585bps to 596.06% in 2024, then surged by 39bps to 363.56% in 2025.
  • Business Quant data shows EBT Margin for CHRS at 363.56% in Q4 2025, 384.73% in Q3 2025, and 437.51% in Q2 2025.